Whitepaper

The whitepaper highlights how protein kinases, which regulate various cellular functions and include about 560 enzymes in the human genome, are linked to cancers and other disorders. Since 2001, over 75 small molecule kinase inhibitors (SMKIs) have been approved by the FDA, primarily for oncology, and new areas are emerging. SMKIs are classified into seven classes based on their binding mode, target, and enzyme state. 

SMKI synthesis is a complex process involving diverse chemistry, often utilizing metal-catalyzed cross-coupling. Large-scale GMP manufacturing necessitates control over catalyst deactivation, impurity formation, and residual metals. The recycling of precious metals is crucial for cost and sustainability. In this intricate landscape, manufacturers require versatile technology and robust safety measures, a need that Axplora is adept at fulfilling for potent compounds.